^
Association details:
| Biomarker: | MET overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | MYTX-011 (Microtubule inhibitor, c-MET-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
Published date:
09/26/2023
Excerpt:
Mythic Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mythic’s investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.
